Gastroenteropancreatic Neuroendocrine Tumors Rise as Endoscopy Improves Detection

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent the most common subtype of neuroendocrine tumors, a diverse group of cancers with varying biological behaviors and clinical outcomes. This matters because GEP-NET incidence has dramatically increased over recent decades, making understanding of these tumors increasingly important for both patients and healthcare providers.

This comprehensive review analyzed current knowledge about GEP-NETs, focusing on diagnostic strategies, treatment advances, and the evolving role of endoscopy in patient care. The authors examined incidence trends, pathologic classification systems, and therapeutic options across the spectrum of disease severity.

Key findings reveal that rising GEP-NET rates stem primarily from improved diagnostic capabilities and increased endoscopic procedures, though environmental factors may also contribute. The 2022 WHO classification system now guides treatment decisions based on tumor grade and stage. Advanced imaging like somatostatin receptor PET scans enables precise tumor localization. Treatment has evolved from primarily surgical approaches to include endoscopic management for indolent tumors and novel targeted therapies for advanced disease.

These advances have significant implications for patient outcomes. Early-stage tumors can now be managed less invasively through endoscopy, while patients with metastatic disease have access to effective treatments including somatostatin analogs, radioligand therapy, and mTOR inhibitors. However, the authors emphasize that future research must identify molecular markers for personalized treatment and better define which tumors are appropriate for endoscopic therapy versus surgical intervention.